8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Jan 12, 2026·SEC
Acumen Pharmaceuticals, Inc.(ABOS)Earnings, Financials & Key Ratios
ABOS•NASDAQ
$2.57
$156M mkt cap·Price updated May 6, 2026
AboutAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Show more
- Revenue$0
- EBITDA-$114M-86.8%
- Net Income-$102M-95.4%
- EPS (Diluted)-1.71-58.3%
- ROE-45.6%-98.4%
- ROIC-42.28%-32.5%
- Debt/Equity0.16+53.1%
- Interest Coverage-28.03+73.4%
ABOS Key Insights
Acumen Pharmaceuticals, Inc. (ABOS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 23.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ABOS Price & Volume
Acumen Pharmaceuticals, Inc. (ABOS) stock price & volume — 10-year historical chart
Loading chart...
ABOS Growth Metrics
Acumen Pharmaceuticals, Inc. (ABOS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-63.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-62.04%
Return on Capital
10 Years-45.53%
5 Years-28.53%
3 Years-30.62%
Last Year-44.84%
ABOS Recent Earnings
Acumen Pharmaceuticals, Inc. (ABOS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
Mar 26, 2026EPS
$0.41
Est $0.50
+18.0%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.44
Est $0.63
+30.2%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.68
Est $0.54
-25.9%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.48
Est $0.56
+14.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 26, 2026 | $0.41vs $0.50+18.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.44vs $0.63+30.2% | — |
| Q3 2025 | Aug 12, 2025 | $0.68vs $0.54-25.9% | — |
| Q2 2025 | May 13, 2025 | $0.48vs $0.56+14.3% | — |
Based on last 12 quarters of dataView full earnings history →
ABOS Peer Comparison
Acumen Pharmaceuticals, Inc. (ABOS) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ATNM | 38.68M | 1.24 | -0.98 | -100% | -384.43% | -151.67% | 0.05 | |
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 ACIU | 302.27M | 2.97 | -3.31 | -86.92% | -19.69% | -101.6% | 0.10 | |
 ANVS | 65.28M | 2.40 | -1.71 | -0.68% | ||||
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ESPR | 753.05M | 3.15 | -28.64 | 21.31% | -5.63% |
Compare ABOS vs Peers
Acumen Pharmaceuticals, Inc. (ABOS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABOS Income Statement
Acumen Pharmaceuticals, Inc. (ABOS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.7M | 1.44M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | -15.38% | -100% | - | - | - | - |
| Cost of Goods Sold | 8.58M | 8M | 12.3M | 0 | 0 | 0 | 44K |
| COGS % of Revenue | 505.36% | 556.89% | - | - | - | - | - |
| Gross Profit | -6.88M▲ 0% | -6.56M▲ 4.6% | -12.3M▼ 87.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -44K▲ 0% |
| Gross Margin % | -405.36% | -456.89% | - | - | - | - | - |
| Gross Profit Growth % | - | 4.62% | -87.55% | 100% | - | - | - |
| Operating Expenses | 926K | 1.35M | 7.28M | 45.24M | 61.14M | 114.02M | 138.19M |
| OpEx % of Revenue | 54.57% | 94.08% | - | - | - | - | - |
| Selling, General & Admin | 926K | 1.35M | 7.28M | 12.88M | 18.82M | 20.22M | 19.3M |
| SG&A % of Revenue | 54.57% | 94.08% | - | - | - | - | - |
| Research & Development | 8.58M | 8M | 12.3M | 32.36M | 42.32M | 93.8M | 118.93M |
| R&D % of Revenue | 505.36% | 556.89% | - | - | - | - | - |
| Other Operating Expenses | -8.58M | -8M | -12.3M | 0 | 0 | 0 | 0 |
| Operating Income | -7.8M▲ 0% | -7.91M▼ 1.4% | -19.58M▼ 147.5% | -45.24M▼ 131.0% | -61.14M▼ 35.2% | -114.02M▼ 86.5% | -138.23M▲ 0% |
| Operating Margin % | -459.93% | -550.97% | - | - | - | - | - |
| Operating Income Growth % | - | -1.37% | -147.52% | -130.99% | -35.15% | -86.49% | - |
| EBITDA | 0 | -7.91M | -19.58M | -45.07M | -60.95M | -113.84M | -136.96M |
| EBITDA Margin % | - | -550.97% | - | - | - | - | - |
| EBITDA Growth % | - | - | -147.47% | -130.17% | -35.25% | -86.76% | -47.7% |
| D&A (Non-Cash Add-back) | 7.8M | 0 | 4K | 169K | 184K | 178K | 136K |
| EBIT | -7.8M | -7.91M | -19.58M | -42.86M | -51.79M | -98.26M | -129.18M |
| Net Interest Income | 45K | 1K | 84K | 2.39M | 10.21M | 10.25M | 4.94M |
| Interest Income | 45K | 1K | 84K | 2.39M | 10.79M | 14.32M | 9.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 581K | 4.07M | 4.17M |
| Other Income/Expense | -102K | 587K | -81.02M | 2.38M | 8.77M | 11.69M | 4.88M |
| Pretax Income | -7.91M▲ 0% | -7.33M▲ 7.4% | -100.61M▼ 1273.5% | -42.86M▲ 57.4% | -52.37M▼ 22.2% | -102.33M▼ 95.4% | -133.35M▲ 0% |
| Pretax Margin % | -465.94% | -510.1% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.91M▲ 0% | -7.33M▲ 7.4% | -100.61M▼ 1273.5% | -42.86M▲ 57.4% | -52.37M▼ 22.2% | -102.33M▼ 95.4% | -133.35M▲ 0% |
| Net Margin % | -465.94% | -510.1% | - | - | - | - | - |
| Net Income Growth % | - | 7.36% | -1273.46% | 57.4% | -22.2% | -95.39% | -63.28% |
| Net Income (Continuing) | -7.91M | -7.33M | -100.61M | -42.86M | -52.37M | -102.33M | -133.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.27▲ 0% | -0.26▲ 3.7% | -2.63▼ 911.5% | -1.06▲ 59.7% | -1.08▼ 1.9% | -1.71▼ 58.3% | -2.20▲ 0% |
| EPS Growth % | - | 3.7% | -911.54% | 59.7% | -1.89% | -58.33% | -62.04% |
| EPS (Basic) | -0.20 | -0.26 | -2.63 | -1.06 | -1.08 | -1.71 | - |
| Diluted Shares Outstanding | 28.65M | 28.65M | 38.27M | 40.6M | 48.61M | 60.01M | 60.57M |
| Basic Shares Outstanding | 28.65M | 28.65M | 38.27M | 40.6M | 48.49M | 60.01M | 60.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
ABOS Balance Sheet
Acumen Pharmaceuticals, Inc. (ABOS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.18M | 44.43M | 198.66M | 180.33M | 246.62M | 178.31M | 132.15M |
| Cash & Short-Term Investments | 6.55M | 43.78M | 194.24M | 177.6M | 243.52M | 171.56M | 126.61M |
| Cash Only | 6.55M | 43.78M | 122.16M | 130.1M | 66.89M | 35.63M | 46.83M |
| Short-Term Investments | 0 | 0 | 72.08M | 47.5M | 176.64M | 135.93M | 79.78M |
| Accounts Receivable | 30K | 109K | 0 | 0 | 225K | 0 | 379K |
| Days Sales Outstanding | 6.45 | 27.71 | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 199K | 0 | 159K | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | 329.74 |
| Other Current Assets | 7K | 447K | 2.83M | 1.42M | 1.96M | 5.73M | 4.46M |
| Total Non-Current Assets | 144K | 0 | 31.67M | 16.26M | 63.51M | 60.69M | 10.07M |
| Property, Plant & Equipment | 0 | 0 | 36K | 270K | 503K | 339K | 288K |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 169K | 0 | 30K |
| Long-Term Investments | 0 | 0 | 31.62M | 15.84M | 62.55M | 59.97M | 141M |
| Other Non-Current Assets | 144K | 0 | 14K | 151K | 285K | 379K | 1.3M |
| Total Assets | 7.32M▲ 0% | 44.43M▲ 506.8% | 230.33M▲ 418.4% | 196.59M▼ 14.6% | 310.13M▲ 57.8% | 238.99M▼ 22.9% | 142.22M▲ 0% |
| Asset Turnover | 0.23x | 0.03x | - | - | - | - | 0.00x |
| Asset Growth % | - | 506.79% | 418.42% | -14.65% | 57.75% | -22.94% | -142.23% |
| Total Current Liabilities | 1.34M | 6.37M | 5.15M | 7.81M | 12.97M | 27.61M | 21.96M |
| Accounts Payable | 223K | 531K | 1.09M | 1.64M | 1.38M | 5.65M | 682K |
| Days Payables Outstanding | 9.49 | 24.24 | 32.27 | - | - | - | 19.68K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 3.6M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 614K | 5.5M | 2.96M | 131K | 3.9M | 230K | 4.73M |
| Current Ratio | 5.35x | 6.98x | 38.60x | 23.08x | 19.01x | 6.46x | 6.46x |
| Quick Ratio | 5.35x | 6.98x | 38.60x | 23.06x | 19.01x | 6.45x | 6.45x |
| Cash Conversion Cycle | - | - | - | - | - | - | -19.35K |
| Total Non-Current Liabilities | 17.4M | 56.65M | 0 | 0 | 30.18M | 29.57M | 27.09M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 27.34M | 29.42M | 27.05M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 284K | 150K | 380K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 17.4M | 56.65M | 0 | 0 | 2.56M | 0 | 780K |
| Total Liabilities | 18.74M | 63.02M | 5.15M | 7.81M | 43.15M | 57.18M | 49.05M |
| Total Debt | 0 | 0 | 0 | 105K | 28.49M | 29.7M | 30.84M |
| Net Debt | -6.55M | -43.78M | -122.16M | -130M | -38.4M | -5.92M | -16M |
| Debt / Equity | - | - | - | 0.00x | 0.11x | 0.16x | 0.16x |
| Debt / EBITDA | - | - | - | - | - | - | -0.23x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.12x |
| Interest Coverage | - | - | - | - | -105.23x | -28.03x | -30.95x |
| Total Equity | -11.42M▲ 0% | -18.59M▼ 62.8% | 225.18M▲ 1311.2% | 188.78M▼ 16.2% | 266.97M▲ 41.4% | 181.82M▼ 31.9% | 93.17M▲ 0% |
| Equity Growth % | - | -62.79% | 1311.25% | -16.17% | 41.42% | -31.9% | -181.66% |
| Book Value per Share | -0.40 | -0.65 | 5.88 | 4.65 | 5.49 | 3.03 | 1.54 |
| Total Shareholders' Equity | -11.42M | -18.59M | 225.18M | 188.78M | 266.97M | 181.82M | 93.17M |
| Common Stock | 0 | 0 | 4K | 4K | 6K | 6K | 6K |
| Retained Earnings | -19.64M | -26.96M | -127.57M | -170.43M | -222.8M | -325.13M | -421.32M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -231K | -751K | 312K | -48K | 109K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABOS Cash Flow Statement
Acumen Pharmaceuticals, Inc. (ABOS) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.82M | -7.45M | -17.96M | -35.15M | -43.06M | -86.22M | -86.22M |
| Operating CF Margin % | -401.77% | -518.8% | - | - | - | - | - |
| Operating CF Growth % | - | -9.27% | -141.09% | -95.72% | -22.5% | -100.2% | -434.75% |
| Net Income | -7.91M | -7.33M | -100.61M | -42.86M | -52.37M | -102.33M | -133.35M |
| Depreciation & Amortization | 0 | 0 | 4K | 169K | 184K | 178K | 136K |
| Stock-Based Compensation | 174K | 154K | 922K | 3.06M | 6.14M | 9.63M | 4.97M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 147K | -586K | 81.42M | 487K | -888K | -5.35M | 4.48M |
| Working Capital Changes | 768K | 307K | 298K | 3.99M | 3.87M | 11.65M | 108K |
| Change in Receivables | 200K | -79K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 110K | 308K | 557K | 552K | -261K | 4.27M | -1.66M |
| Cash from Investing | 0 | 0 | -104.12M | 39.19M | -171.67M | 48.03M | 137.35M |
| Capital Expenditures | 0 | 0 | -40K | -161K | -21K | -16K | -88K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | -39.35K | 3K | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 39.35K | 0 | 0 | 0 |
| Cash from Financing | 6.24M | 44.67M | 200.47M | 3.91M | 151.75M | 6.93M | -45K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 30M | -739K | -739K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -82K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -41K | -82K |
| Other Financing | 7K | 0 | 1.88M | 115K | -151K | -230K | 776K |
| Net Change in Cash | -579K▲ 0% | 37.23M▲ 6529.2% | 78.39M▲ 110.6% | 7.94M▼ 89.9% | -62.98M▼ 893.3% | -31.26M▲ 50.4% | 13.65M▲ 0% |
| Free Cash Flow | -6.82M▲ 0% | -7.45M▼ 9.3% | -18M▼ 141.6% | -35.31M▼ 96.2% | -43.09M▼ 22.0% | -86.23M▼ 100.1% | -123.75M▲ 0% |
| FCF Margin % | -401.77% | -518.8% | - | - | - | - | - |
| FCF Growth % | - | -9.27% | -141.62% | -96.18% | -22.01% | -100.14% | -83.75% |
| FCF per Share | -0.24 | -0.26 | -0.47 | -0.87 | -0.89 | -1.44 | -1.44 |
| FCF Conversion (FCF/Net Income) | 0.86x | 1.02x | 0.18x | 0.82x | 0.82x | 0.84x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 1.46M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABOS Key Ratios
Acumen Pharmaceuticals, Inc. (ABOS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -97.4% | -20.71% | -22.98% | -45.6% | -143.12% |
| Return on Invested Capital (ROIC) | - | -72.26% | -41.94% | -31.91% | -42.28% | -42.28% |
| Gross Margin | -456.89% | - | - | - | - | - |
| Net Margin | -510.1% | - | - | - | - | - |
| Debt / Equity | - | - | 0.00x | 0.11x | 0.16x | 0.16x |
| Interest Coverage | - | - | - | -105.23x | -28.03x | -30.95x |
| FCF Conversion | 1.02x | 0.18x | 0.82x | 0.82x | 0.84x | 0.93x |
| Revenue Growth | -15.38% | -100% | - | - | - | - |
ABOS SEC Filings & Documents
Acumen Pharmaceuticals, Inc. (ABOS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ABOS Frequently Asked Questions
Acumen Pharmaceuticals, Inc. (ABOS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Acumen Pharmaceuticals, Inc. (ABOS) grew revenue by 0.0% over the past year. Growth has been modest.
Acumen Pharmaceuticals, Inc. (ABOS) reported a net loss of $133.4M for fiscal year 2024.
Dividend & Returns
Acumen Pharmaceuticals, Inc. (ABOS) has a return on equity (ROE) of -45.6%. Negative ROE indicates the company is unprofitable.
Acumen Pharmaceuticals, Inc. (ABOS) had negative free cash flow of $123.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More ABOS
Acumen Pharmaceuticals, Inc. (ABOS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates